These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
291 related items for PubMed ID: 11513177
1. Infliximab for refractory ulcerative colitis. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Am J Gastroenterol; 2001 Aug; 96(8):2373-81. PubMed ID: 11513177 [Abstract] [Full Text] [Related]
2. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. Yamamoto-Furusho JK, Uzcanga LF. Dig Surg; 2008 Aug; 25(5):383-6. PubMed ID: 19005257 [Abstract] [Full Text] [Related]
3. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Yamamoto S, Nakase H, Matsuura M, Honzawa Y, Masuda S, Inui K, Chiba T. J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441 [Abstract] [Full Text] [Related]
4. A review of infliximab use in ulcerative colitis. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261 [Abstract] [Full Text] [Related]
5. Infliximab in the treatment of severe ulcerative colitis: a follow-up study. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Eur Rev Med Pharmacol Sci; 2004 Feb; 8(5):235-7. PubMed ID: 15638237 [Abstract] [Full Text] [Related]
6. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Viscido A, Annese V, Riegler G, Meucci G, Marrollo M, Sostegni R, Gasbarrini A, Peralta S, Prantera C. Aliment Pharmacol Ther; 2007 Sep 01; 26(5):747-56. PubMed ID: 17697208 [Abstract] [Full Text] [Related]
7. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Jakobovits SL, Jewell DP, Travis SP. Aliment Pharmacol Ther; 2007 May 01; 25(9):1055-60. PubMed ID: 17439506 [Abstract] [Full Text] [Related]
8. [Infliximab in moderate to severe steroid-dependent or steroid-refractory ulcerative colitis]. Mocciaro F, Orlando A, Scimeca D, Cottone M. Recenti Prog Med; 2007 Nov 01; 98(11):560-4. PubMed ID: 18044405 [Abstract] [Full Text] [Related]
9. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Am J Gastroenterol; 2002 Oct 01; 97(10):2577-84. PubMed ID: 12385442 [Abstract] [Full Text] [Related]
10. Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH, Walters J, Carpani M, Westaby D, Thillainayagam A, Bansi D, Ghosh S. Aliment Pharmacol Ther; 2009 Feb 01; 29(3):308-14. PubMed ID: 19035973 [Abstract] [Full Text] [Related]
11. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Herrlinger KR, Barthel DN, Schmidt KJ, Büning J, Barthel CS, Wehkamp J, Stange EF, Fellermann K. Aliment Pharmacol Ther; 2010 May 01; 31(9):1036-41. PubMed ID: 20175769 [Abstract] [Full Text] [Related]
12. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Kaser A, Mairinger T, Vogel W, Tilg H. Wien Klin Wochenschr; 2001 Dec 17; 113(23-24):930-3. PubMed ID: 11802508 [Abstract] [Full Text] [Related]
13. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourié B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. Am J Gastroenterol; 2010 Dec 17; 105(12):2617-25. PubMed ID: 20736936 [Abstract] [Full Text] [Related]
14. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. Fratila OC, Craciun C. J Gastrointestin Liver Dis; 2010 Jun 17; 19(2):147-53. PubMed ID: 20593047 [Abstract] [Full Text] [Related]
15. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, Marano CW, Strauss R, Oddens BJ, Feagan BG, Hanauer SB, Lichtenstein GR, Present D, Sands BE, Sandborn WJ. Gastroenterology; 2011 Oct 17; 141(4):1194-201. PubMed ID: 21723220 [Abstract] [Full Text] [Related]
16. Infliximab in the treatment of steroid-dependent ulcerative colitis. Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A. Eur Rev Med Pharmacol Sci; 2004 Oct 17; 8(5):231-3. PubMed ID: 15638236 [Abstract] [Full Text] [Related]
17. Infliximab for patients with refractory ulcerative colitis. Chey WY. Inflamm Bowel Dis; 2001 May 17; 7 Suppl 1():S30-3. PubMed ID: 11380041 [Abstract] [Full Text] [Related]
18. Infliximab for ulcerative colitis following liver transplantation. Lal S, Steinhart AH. Eur J Gastroenterol Hepatol; 2007 Mar 17; 19(3):277-80. PubMed ID: 17301656 [Abstract] [Full Text] [Related]
19. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R. Dig Liver Dis; 2008 Oct 17; 40(10):821-6. PubMed ID: 18472316 [Abstract] [Full Text] [Related]
20. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Jürgens M, Laubender RP, Hartl F, Weidinger M, Seiderer J, Wagner J, Wetzke M, Beigel F, Pfennig S, Stallhofer J, Schnitzler F, Tillack C, Lohse P, Göke B, Glas J, Ochsenkühn T, Brand S. Am J Gastroenterol; 2010 Aug 17; 105(8):1811-9. PubMed ID: 20197757 [Abstract] [Full Text] [Related] Page: [Next] [New Search]